Clinical Trial Update: Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update of atezolizumab, guadecitabine, and CDX-1401 vaccine in recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CDX-1401 Vaccine (CDX-1401 vaccine)
• Guadecitabine (guadecitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1, Phase 2 | Status: COMPLETED